Recruiting studies: Relapsed Refractory Kmt2A R Acute Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184 BY002 IIT Study in R/R Acute Leukemia
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07270770 Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Phase 1 · 20 location(s) · PedAL BCU, LLC · NCT06376162 A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.